Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 5, 2003

View Archived Issues

Completion of phase I study of vaccinia immune globulin

Screening commences for phase II study of Prosaptide

Advanced Biotherapy to study antibody therapy in organ transplant rejection

Roche presents novel DPP-IV inhibitors in a recent patent

New HIV protease inhibitors prepared and tested at Tibotec-Virco

Lundbeck claims glycine transport inhibitors and their use in psychosis, cognition disorders, etc.

Novel PDE7 inhibitors and their use reported by Daiichi Suntory and Suntory scientists

HNE inhibitors with potential in COPD therapy covered by Bayer patent

Bayer researchers design adenosine A1 receptor agonists for ischemic disorders

New mGluR1 antagonists in early development at Bayer

Two series of adenosine A3 receptor antagonists described by Sanofi-Synthelabo

Analgesic effects reported for KRN-5500 in a murine model of neuropathic pain

Potential use of interferon in the therapy of SARS

Priority review for diquafosol tetrasodium NDA

Bexxar launched in U.S.

Small-molecule Bcl-2 inhibitor with apoptosis-inducing effects in cancer cells

Cytogen completes reacquisition of Quadramet marketing rights

Evotec Neurosciences and Takeda form Alzheimer's collaboration

Maxim discusses discovery and development of apoptosis inducers at cancer meeting

Enbrel approved to improve physical function in RA patients

FDA approves Zavesca for type 1 Gaucher's disease

Japan Tobacco to commercialize Gilead HIV products in Japan

FDA advisory committee sets review date for Raptiva

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...